EYPT News and Press, EyePoint Pharmaceuticals Inc. From 11/24/23

2023-11-24 13:00:31 ET More on the markets Broad Turn In Weekly Momentum Bodes Well For Stocks SPY: When Indicators Speak, The Year-End Rally Makes Little Sense 2024 U.S. Equities Outlook: Expect Bulls To Win This Round, Too Best stocks for when the 10-year T...

2023-11-08 08:04:15 ET Summary EYP-1901 shows potential in wet AMD, underpinned by EyePoint's financial stability and innovative Durasert technology. Despite a decrease in product sales, increased R&D spend and a stable cash position suggest a robust pipeline focus. The DA...

2023-11-06 08:40:13 ET More on Health Care Stocks Merck therapy shows improved survival in certain kidney cancer patients Pfizer: Ignore The Noise And Buy This Deep Value AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio Arexvy Put...

2023-11-01 13:03:08 ET EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call November 1, 2023, 08:30 AM ET Company Participants George Elston - EVP and CFO Jay Duker - President and CEO Conference Call Participants Tyler Van Buren - Cowen...

2023-11-01 07:20:22 ET More on EyePoint Pharmaceuticals EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks EyePoint spikes after safety update on lead asset Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals Historical earnings data f...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership strengthened with the appointment of Stuart Duty to the Board of Di...

EyePoint Pharmaceuticals Inc. (EYPT) is expected to report $-0.62 for Q3 2023

2023-10-31 12:01:33 ET More on EyePoint Pharmaceuticals EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks EyePoint spikes after safety update on lead asset Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals Historical earnings data f...

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, today announced it will host a virtual key opinion leader (KOL) event on Th...